Sightline Wealth Advisors LLC Has $421,000 Stake in Global X Genomics & Biotechnology ETF $GNOM

Sightline Wealth Advisors LLC decreased its holdings in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) by 78.2% in the 3rd quarter, HoldingsChannel reports. The firm owned 10,832 shares of the company’s stock after selling 38,796 shares during the quarter. Sightline Wealth Advisors LLC’s holdings in Global X Genomics & Biotechnology ETF were worth $421,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Jane Street Group LLC raised its holdings in shares of Global X Genomics & Biotechnology ETF by 7.7% in the first quarter. Jane Street Group LLC now owns 143,713 shares of the company’s stock valued at $1,143,000 after buying an additional 10,308 shares during the last quarter. Halbert Hargrove Global Advisors LLC increased its position in Global X Genomics & Biotechnology ETF by 182.4% in the 2nd quarter. Halbert Hargrove Global Advisors LLC now owns 13,685 shares of the company’s stock valued at $115,000 after acquiring an additional 8,839 shares in the last quarter. Insight Advisors LLC PA raised its stake in shares of Global X Genomics & Biotechnology ETF by 47.9% in the second quarter. Insight Advisors LLC PA now owns 59,675 shares of the company’s stock worth $503,000 after acquiring an additional 19,319 shares during the last quarter. Oppenheimer Asset Management Inc. lifted its position in shares of Global X Genomics & Biotechnology ETF by 8.1% during the second quarter. Oppenheimer Asset Management Inc. now owns 89,631 shares of the company’s stock worth $756,000 after purchasing an additional 6,708 shares in the last quarter. Finally, Atria Investments Inc grew its stake in shares of Global X Genomics & Biotechnology ETF by 12.6% during the second quarter. Atria Investments Inc now owns 18,520 shares of the company’s stock valued at $156,000 after purchasing an additional 2,073 shares during the last quarter. Institutional investors own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Price Performance

GNOM stock opened at $49.31 on Tuesday. The company has a 50 day moving average price of $46.77 and a 200 day moving average price of $41.58. Global X Genomics & Biotechnology ETF has a fifty-two week low of $27.20 and a fifty-two week high of $51.42. The stock has a market capitalization of $53.75 million, a PE ratio of -21.07 and a beta of 1.22.

Global X Genomics & Biotechnology ETF Announces Dividend

The company also recently declared a dividend, which was paid on Wednesday, January 7th. Investors of record on Tuesday, December 30th were issued a $0.5912 dividend. The ex-dividend date was Tuesday, December 30th. This represents a yield of 259.0%. Global X Genomics & Biotechnology ETF’s dividend payout ratio (DPR) is currently -26.50%.

Global X Genomics & Biotechnology ETF Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.